Compare CUBI & DAWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CUBI | DAWN |
|---|---|---|
| Founded | 1994 | 2018 |
| Country | United States | United States |
| Employees | 869 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.2B |
| IPO Year | N/A | 2021 |
| Metric | CUBI | DAWN |
|---|---|---|
| Price | $76.01 | $21.50 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 8 |
| Target Price | ★ $85.00 | $24.43 |
| AVG Volume (30 Days) | 300.9K | ★ 1.4M |
| Earning Date | 04-23-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $158,182,000.00 |
| Revenue This Year | $24.95 | $55.03 |
| Revenue Next Year | $9.50 | $28.12 |
| P/E Ratio | $11.78 | ★ N/A |
| Revenue Growth | N/A | ★ 20.60 |
| 52 Week Low | $49.76 | $5.64 |
| 52 Week High | $82.56 | $21.53 |
| Indicator | CUBI | DAWN |
|---|---|---|
| Relative Strength Index (RSI) | 55.09 | 80.29 |
| Support Level | $71.59 | $10.30 |
| Resistance Level | $79.23 | N/A |
| Average True Range (ATR) | 2.29 | 0.03 |
| MACD | -0.19 | -0.28 |
| Stochastic Oscillator | 52.88 | 90.91 |
Customers Bancorp Inc is a bank holding company conducting banking activities through its wholly owned subsidiary, Customers Bank. The Bank provides commercial and consumer customers the stability of a regulated financial institution supported by risk management. It serves commercial and corporate businesses nationwide, including healthcare, real estate, specialty finance, fund finance, technology and venture capital banking, mortgage finance and commercial equipment financing, and provides payments and treasury services. The Bank also serves consumers through its branch network, offering residential mortgages and personal loan and deposit products, including Banking-as-a-Service, with services delivered predominantly in Southeastern and Central Pennsylvania, New York, and other states.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY301 is an antibody drug conjugate (ADC) that has shown antitumor activity in preclinical models.